[1] FRIEDMAN SL. Hepatic fibrosis-overview[J]. Toxicology,2008,254(3):120-129.
|
[2] LIN SR,QIAN JM,ZHOU LY,et al. Digestive internal medicine[M]. Beijing:People’s Military Medical Press,2013:377-381.(in Chinese)林三仁,钱家鸣,周丽雅,等.消化内科学[M].北京:人民军医出版社,2013:377-381.
|
[3] PATELL K,BEDOSSA P,CASTERA L. Diagnosis of liver fibrosis:Present and future[J]. Liver Dis,2015,35(2):166-183.
|
[4] FOUAD SA,ESMAT S,OMRAN D,et al. Noninvasive assessment of hepatic fibrosis in Egyptian patients with chronic hepatitis C virus infection[J]. World J Gastroenterol,2012,18(23):2988-2994.
|
[5] EBRAHIMI H,NADERIAN M,SOHRABPOUR AA. New concepts on pathogenesis,diagnosis,and targeting of liver fibrosis; A review article[J]. Middle East J Did Dis,2016,8(3):166-178.
|
[6] KASWALA DH,LAI M,AFDHAL NH. Fibrosis assessment in nonalcoholic fatty liver disease(NAFLD)in 2016[J]. Dig Dis Sci,2016,61(5):1356-1364.
|
[7] VALKHOFF VE,STURKENBOOM MC,KUIPERS EJ. Risk factors for gastrointestinalbleeding associated with low-dose aspirin[J]. Best Pract Res Clin Gastroenterol,2012,26(2):125-140.
|
[8] GAMALl S,ALAA I,AHMED H,et al. Asian-Pacific Association for the Study of the Liver(APASL)consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis:A 2016 update[J]. Hepatol Int,2017,11(1):1-30.
|
[9] FUKUI H,SAITO H,UENO Y,et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015[J]. J Gastroenterol,2016,51(7):629-650.
|
[10] TERRAULT NA,LOK ASF,MCMAHON BJ,et al. Update on prevention,diagnosis,and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance[J]. Hepatology,2018,67(4):1560-1599.
|
[11] National Health and Family Planning Comission of The People’s Republic of China. WS213-2018 Diagnosis for hepatitis C[J]. J Clin Hepatol,2018,34(8):1619-1621.(in Chinese)中华人民共和国国家卫生和计划生育委员会.WS213-2018丙型肝炎诊断[J].临床肝胆病杂志,2018,34(8):1619-1621.
|
[12] National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association;Fatty Liver Expert Committee,Chinese Medical Doctor Association. Guidelines of prevention and treatment for alcoholic liver disease:A 2018 update[J]. J Clin Hepatol,2018,34(5):939-946.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.酒精性肝病防治指南(2018年更新版)[J].临床肝胆病杂志,2018,34(5):939-946.
|
[13] CHEN HZ,ZHONG NS,LU ZY. Internal medicine[M]. 9th ed. Beijing:People’s Health Publishing House,2018:385-399.(in Chinese)陈灏珠,钟南山,陆再英.内科学[M]. 9版.北京:人民卫生出版社,2018:385-399.
|
[14] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(V2017)[J]. J Clin Hepatol,2017,33(8):1419-1431.(in Chinese)中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范(2017年版)[J].临床肝胆病杂志,2017,33(8):1419-1431.
|
[15] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Infectious Diseases,Chinese Medical Association. Consensus on the diagnosis and management of autoimmune hepatitis(2015)[J]. J Clin Hepatol,2016,32(1):9-22.(in Chinese)中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会.自身免疫性肝炎诊断和治疗共识(2015)[J].临床肝胆病杂志,2016,32(1):9-22.
|
[16] National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association;Fatty Liver Expert Committee,Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J]. J Clin Hepatol,2018,34(5):947-957.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪肝肝病防治指南(2018更新版)[J].临床肝胆病杂志,2018,34(5):947-957.
|
[17] LIU T,XU MY. Serologic diagnosis of liver fibrosis[J]. J Prac Hepatol,2016,19(1):1-4.(in Chinese)刘婷,徐铭益.肝纤维化的血清学诊断研究进展[J].实用肝脏病杂志,2016,19(1):1-4.
|
[18] RODERFELD M,HEMMANN S,ROEB E. Mechanisms of fibrinolysis in chronic liver injury(with special emphasis on MMPs and TIMPs)[J]. Z Gastroenterol,2007,45(1):25-33.
|
[19] MAHMOUD AA,BAKIR AS,SHABANA SS. Serum TGF-β,Serum MMP-1,and HOMA-IR as non-invasive predictors of fibrosis in Egyptian patients with NAFLD[J]. Saudi J Gastroenterol,2012,18(5):327-333.
|
[20] SAITOU Y,SHIRAKI K,YAMANAKA Y. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker,YKL-40,in patients with HCV-associated liver disease[J]. World J Gastroenterol,2005,11(4):476-481.
|
[21] AHMED S,ABEDEL H,LAILA N,et al. Role of fibroscan,TGF-β1,and YKL-40 in the detection of hepatic fibrosis in chronic hepatitis C patients with and without schistosomiasis[J]. Egypt Liver J,2015,5(3):47-53.
|
[22] ZHANG HY,ZHANG Y,WANG XH,et al. Value of IGFBPr P1and contrast-enhanced ultrasound in liver fibrosis staging with rabbits[J]. Int J Clin Exp Med,2017,10(8):11606-11615.
|
[23] UMEMURA T,JOSHITA S,SEKIGUCHI T,et al. Serum wisteria floribunda agglutinin-positive mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis[J]. Am J Gastroenterol,2015,110(6):857-864.
|
[24] LIU LX,LYU TT. A challenge of serological diagnosis in liver fibrosis[J/CD]. Chin J Digest Med Imageol:Electronic Edition,2018,8(1):1-6.(in Chinese)刘立新,吕婷婷.肝纤维化血清学诊断标记物[J/CD].中华消化病与影像杂志:电子版,2018,8(1):1-6.
|
[25] LIN YM,WANG YL,HE M,et,al. Clinical significance of combined determination of liver fibrosis indexes from liver disease patients’serum[J]. Chongqing Med,2014,43(29):3921-3922.(in Chinese)林一民,王云龙,何萌,等.肝病患者血清肝纤维化指标联合测定的临床意义[J].重庆医学,2014,43(29):3921-3922.
|
[26] SORESI M,GIANNITRAPANI L,CERVELLO M,et al. Non invasive tools for the diagnosis of liver cirrhosis[J]. World J Gastroenterol,2014,20(48):18131-18150.
|
[27] DONG FC,LONG JL,LIN LQ,et al. The value of serum fibrosis indexes combined with liver function tests in the evaluation of hepatic fibrosis in patients with hepatitis B[J]. J Shenyang Med Coll,2018,20(3):224-226.(in Chinese)董福昌,龙健灵,林丽卿,等.血清肝纤维化指标联合肝生化检测对乙肝患者肝纤维化的评估[J].沈阳医学院学报,2018,20(3):224-226.
|
[28] MAZZARA S,SINISI A,CARDACI A,et al. Two of them do it better:Novel serum biomarkers improve autoimmune hepatitis diagnosis[J]. PLo S One,2015,10(9):e0137927.
|
[29] GRESSNER AM,RIZK M,GAO CF,et al. Potential novel biomarkers for monitoring the fibrogenic process in liver[J]. Arab J Gastroenterol,2010,10(4):s12-s16.
|
[30] DU W,SHAN YL,LIAO QL,et,al. Clinical significances of HA,PⅢNP,LN and CⅣin the diagnosis of chronic liver disease and liver fibrosis[J]. J Chongqing Med Univ,2013,38(5):530-533.(in Chinese)杜伟,单幼兰,廖权利,等.HA、PⅢNP、LN、CⅣ在慢性肝病及肝纤维化诊断中的临床意义[J].重庆医科大学学报,2013,38(5):530-533.
|
[31] CALES P,OBERTI F,MIEHAIAK S,et al. A novel panel of blood markers to assess the degree of liver fibrosis[J]. Hepatology,2005,42(6):1373-1381.
|